Literature DB >> 26683416

Injectable collagenase Clostridium histolyticum as a nonsurgical treatment for Dupuytren's disease.

R Arora1, P Kaiser2, T-J Kastenberger2, G Schmiedle2, S Erhart2, M Gabl2.   

Abstract

OBJECTIVE: Nonsurgical treatment of Dupuytren's disease using collagenase Clostridium histolyticum (CCH). INDICATIONS: Metacarpophalangeal (MP) joint (20-100°) and proximal interphalangeal (PIP) joint (20-80°) contractures. CONTRAINDICATIONS: Pregnancy, previous hypersensitivity to collagenase or excipients, anticoagulant use within 7 days prior to treatment. INJECTION TECHNIQUE: CCH injected directly into the Dupuytren's cord weakening the contracted cord. After injection, the patient returns the following day to allow CCH to lyse the collagen within the cord. An extension force is then applied to the involved finger to disrupt the weakened cord. POSTMANIPULATION MANAGEMENT: Use of extension splint at night, movement instructions during the day.
RESULTS: A total of 120 patients (107 men; 13 women; mean age 62 years, range 30-84 years) were treated. In 49% the little finger, in 44% the ring finger, in 4% the middle finger, and in 3% the index finger was treated. Full release was achieved in 71%, partial release in 26%, and no change in 3% of patients. The median pretreatment contracture for the MP joint was 37° (range 25-100°) and PIP joint 51° (range 30-97°). At 12 months, the mean contracture for the MP joint was 9° (range 0-25°) and for the PIP joint 21° (range 10-36°). Adverse events observed in 96% of patients for 3 months . No tendon ruptures, anaphylactic reactions, or nerve or ligament injuries observed.

Entities:  

Keywords:  Collagenase treatment; Dupuytren contracture; Fingers; Hand; Non surgical treatment

Mesh:

Substances:

Year:  2015        PMID: 26683416     DOI: 10.1007/s00064-015-0434-4

Source DB:  PubMed          Journal:  Oper Orthop Traumatol        ISSN: 0934-6694            Impact factor:   1.154


  9 in total

Review 1.  Nonoperative treatment of Dupuytren's disease.

Authors:  L C Hurst; M A Badalamente
Journal:  Hand Clin       Date:  1999-02       Impact factor: 1.907

Review 2.  Assessment of clinical severity in Dupuytren's disease.

Authors:  A Bayat; E J Cunliffe; D A McGrouther
Journal:  Br J Hosp Med (Lond)       Date:  2007-11       Impact factor: 0.825

Review 3.  Dupuytren's disease: history, diagnosis, and treatment.

Authors:  Robert B Shaw; Alphonsus K S Chong; Andrew Zhang; Vincent R Hentz; James Chang
Journal:  Plast Reconstr Surg       Date:  2007-09       Impact factor: 4.730

Review 4.  The treatment of Dupuytren disease.

Authors:  Shaunak S Desai; Vincent R Hentz
Journal:  J Hand Surg Am       Date:  2011-05       Impact factor: 2.230

5.  Collagenase in the treatment of Dupuytren's disease: an in vitro study.

Authors:  K D Starkweather; S Lattuga; L C Hurst; M A Badalamente; F Guilak; S P Sampson; A Dowd; D Wisch
Journal:  J Hand Surg Am       Date:  1996-05       Impact factor: 2.230

6.  Collagenase injection as nonsurgical treatment of Dupuytren's disease: 8-year follow-up.

Authors:  Andrew J Watt; Catherine M Curtin; Vincent R Hentz
Journal:  J Hand Surg Am       Date:  2010-04       Impact factor: 2.230

7.  Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease.

Authors:  David Gilpin; Stephen Coleman; Stephen Hall; Anthony Houston; Jeff Karrasch; Nigel Jones
Journal:  J Hand Surg Am       Date:  2010-12       Impact factor: 2.230

8.  Collagen as a clinical target: nonoperative treatment of Dupuytren's disease.

Authors:  Marie A Badalamente; Lawrence C Hurst; Vincent R Hentz
Journal:  J Hand Surg Am       Date:  2002-09       Impact factor: 2.230

9.  Injectable collagenase clostridium histolyticum for Dupuytren's contracture.

Authors:  Lawrence C Hurst; Marie A Badalamente; Vincent R Hentz; Robert N Hotchkiss; F Thomas D Kaplan; Roy A Meals; Theodore M Smith; John Rodzvilla
Journal:  N Engl J Med       Date:  2009-09-03       Impact factor: 91.245

  9 in total
  4 in total

1.  Update on the role of molecular factors and fibroblasts in the pathogenesis of Dupuytren's disease.

Authors:  Massimiliano Tripoli; Adriana Cordova; Francesco Moschella
Journal:  J Cell Commun Signal       Date:  2016-06-07       Impact factor: 5.782

2.  [Treatment of Dupuytren's disease with collagenase Clostridium histolyticum].

Authors:  M Keller; R Arora; G Schmiedle; T Kastenberger
Journal:  Orthopade       Date:  2017-04       Impact factor: 1.087

Review 3.  [The fibrous skeleton of the hand : Changes with Dupuytren's contracture].

Authors:  M F Langer; J Grünert; F Unglaub; B Wieskötter; S Oeckenpöhler
Journal:  Orthopade       Date:  2017-04       Impact factor: 1.087

4.  Treatment of Dupuytren's Contracture With Collagenase: A Systematic Review.

Authors:  Alexis B Sandler; John P Scanaliato; Thomas Dennis; Gilberto A Gonzalez Trevizo; Sorana Raiciulescu; Leon Nesti; John C Dunn
Journal:  Hand (N Y)       Date:  2021-01-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.